Smoldering Multiple Myeloma — Trials

Smoldering Multiple Myeloma — Trials · CancerIndex

Clinical trials

Registered studies

85 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 34
Recruiting: 13
Ph III recruiting: 1
Growth YoY: —
Industry share: 9%
Top sponsor: Dana-Farber Cancer Institute
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00114101	Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant	active not recruiting	Phase 3	460	National Cancer Institute (NCI)NIH	1	Aug 26, 2026	clinicaltrials
NCT01169337	Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma	active not recruiting	Phase 3	226	National Cancer Institute (NCI)NIH	3	Aug 4, 2026	clinicaltrials